Imunon (NASDAQ:IMNN – Get Free Report) and Liminatus Pharma (NASDAQ:LIMN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.
Profitability
This table compares Imunon and Liminatus Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Imunon | N/A | -358.01% | -132.91% |
| Liminatus Pharma | N/A | N/A | -256.58% |
Analyst Recommendations
This is a breakdown of current ratings for Imunon and Liminatus Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Imunon | 1 | 0 | 1 | 0 | 2.00 |
| Liminatus Pharma | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Imunon and Liminatus Pharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Imunon | N/A | N/A | -$14.49 million | ($3.83) | -0.41 |
| Liminatus Pharma | N/A | N/A | -$10.21 million | ($23.50) | -0.16 |
Imunon is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
4.5% of Imunon shares are held by institutional investors. 2.8% of Imunon shares are held by company insiders. Comparatively, 19.4% of Liminatus Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Imunon has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Liminatus Pharma has a beta of 5.3, meaning that its share price is 430% more volatile than the S&P 500.
Summary
Imunon beats Liminatus Pharma on 6 of the 11 factors compared between the two stocks.
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
About Liminatus Pharma
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
